1-9 of 9
Thomas Doerr
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Hira Mian, Muhamed Baljevic, Hila Magen, Moshe E Gatt, Irit Avivi Mazza, Emma Searle, Eben I Lichtman, John T. McKay, Torben Plesner, Cesar Rodriguez, Neha Korde, Hana Safah, Iuliana Vaxman, Chetasi Talati, Anders Erik Svensson, Ziyi Jin, Shane Lee, Thomas Doerr, Rajvineeth Kumar Pothacamury, Tanya S Rosenberg, Akshanth R Polepally, Jeremy A. Ross, Shaji Kumar
Journal: Blood
Blood (2024) 144 (Supplement 1): 1985.
https://doi.org/10.1182/blood-2024-206912
Published: 2024
Journal Articles

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Catherine Thieblemont, Yasmin H. Karimi, Chan Y Cheah, Michael Roost Clausen, Kim Linton, Tycel J. Phillips, Franck Morschhauser, Martin Hutchings, Rebekah Conlon, Saurabh Mukhopadhyay, Aurelie Le Maitre, Yu Deng, Mariana Sacchi, Thomas Doerr, Minh Dinh, William Palo, Loretta Nastoupil
Journal: Blood
Blood (2024) 144 (Supplement 1): 4491.
https://doi.org/10.1182/blood-2024-200957
Published: 2024
Journal Articles

Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Jeff P. Sharman, Ralph V. Boccia, Thomas Doerr, Kristin Conte, Yang Bai, Brian Elliott, David J. Andorsky
Journal: Blood
Blood (2022) 140 (Supplement 1): 9491–9492.
https://doi.org/10.1182/blood-2022-157575
Published: 2022
Journal Articles

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis

Kalatu R. Davies, Rajesh Kamalakar, Junhua Yu, Yinan Huang, Anthony Wang, Kavita Sail, Thomas Doerr, Simon Sharmokh, Alex Mutebi, Gilles Salles
Journal: Blood
Blood (2022) 140 (Supplement 1): 5058–5059.
https://doi.org/10.1182/blood-2022-157758
Published: 2022
Journal Articles

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Julia Piasecki, BA, Todd Devries, PhD, Aditya Radhakrishnan, PhD, Yan Li, PhD, Mark Heipel, BS, Brian A. Fox, PhD, Valeria Beckett, MS, Mariana Cota Stirner, MD PhD, Kristin Conte, MPH, Thomas Doerr, MSc, Sham Mailankody, MBBS, Sandy W. Wong, MD, Philip L. McCarthy, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-137786
Published: 2020
Journal Articles

MM-011: A Phase 2 Study of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma in Japan

Shotaro Hagiwara, Shinichiro Okamoto, Kosei Matsue, Shinsuke Iida, Kazutaka Sunami, Takuya Komeno, Kenshi Suzuki, Kiyoshi Ando, Masafumi Taniwaki, Kensei Tobinai, MD PhD, Takaaki Chou, Hitomi Kaneko, Hiromi Iwasaki, MD PhD, Chie Uemura, Hiromi Tamakoshi, Mohamed H Zaki, Thomas Doerr, Yoshiaki Kuroda, Tatsuo Ichinohe, MDPhD
Journal: Blood
Blood (2015) 126 (23): 5374.
https://doi.org/10.1182/blood.V126.23.5374.5374
Published: 2015
Journal Articles

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Shinsuke Iida, Hiromi Iwasaki, MD PhD, Takaaki Chou, Kensei Tobonai, Kazutaka Sunami, Yoshiaki Ogawa, MD, Mari Kurihara, Shuichi Midorikawa, Mohamed H. Zaki, MD, Thomas Doerr, MSc, Kosei Matsue
Journal: Blood
Blood (2014) 124 (21): 2107.
https://doi.org/10.1182/blood.V124.21.2107.2107
Published: 2014
Journal Articles

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment

Jeffrey Matous, MD, David S Siegel, MD PhD, Sagar Lonial, MD, R. Donald Harvey, PharmD, Claudia Kasserra, PhD, Yan Li, PhD, Min Chen, PhD, Thomas Doerr, MSc, Lars Sternas, MD, Mohamed H. Zaki, MD, Christian Jacques, MD, Jatin J. Shah, MD
Journal: Blood
Blood (2014) 124 (21): 4730.
https://doi.org/10.1182/blood.V124.21.4730.4730
Published: 2014
Journal Articles

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment

Jeffrey Matous, MD, David S. Siegel, MD, PhD, Hien K. Duong, MD, Claudia Kasserra, PhD, Min Chen, PhD, Thomas Doerr, MSc, Lars Sternas, MD, Mohamed H. Zaki, MD, PhD, Christian Jacques, MD, Jatin J. Shah, M.D.
Journal: Blood
Blood (2013) 122 (21): 5393.
https://doi.org/10.1182/blood.V122.21.5393.5393
Published: 2013